



Vaxin Inc.

Contact:

Bill Enright

President & CEO

Phone: 205-909-3751

Email: enright@vaxin.com

FOR IMMEDIATE RELEASE

HERBERT L. HEYNEKER, PH.D., TO JOIN VAXIN'S BOARD OF DIRECTORS

Rockville, Maryland – May 4, 2010 – Vaxin Inc., an emerging vaccine company today announced the appointment of Herbert L. Heyneker, Ph.D., to its Board of Directors. Dr. Heyneker's appointment to the Board of Directors is effective as of April 13, 2010.

"We are very pleased to have Herb join our Board," said Lyle A. Hohnke, Ph.D., Chairman of the Board Vaxin. "His impressive scientific and management credentials are a great addition to our Board and his guidance will serve Vaxin well as we strive to develop and commercialize safe, effective, single-dose, needle-free vaccines for a number of indications."

In addition to serving on Vaxin's Board of Directors, Dr. Heyneker acts as an advisor for Abingworth Bioventures and Utrecht-based Thuja Capital scouting for new investment opportunities and performing technical due-diligence. He has founded multiple, successful biotech companies and has held positions with Eos Biotechnology, Inc., ProtoGene Laboratories, Inc., GlycoGen Inc., Genencor International Inc. and was the first scientist hired at Genentech. At Eos, Dr. Heyneker designed a highly parallel DNA synthesis instrument, which was used by a wholly-owned subsidiary of Eos to sell oligos over the web. This business was later acquired by Life technologies. He has also served on the board of directors for GenPharm and Guava Technologies in the US and in the Netherlands, IntroGene (acquired by Crucell), Pharming, Pepscan and Prosensa. He is currently a board member of Profibrix and Boreal Genomics. Additionally, Dr. Heyneker consults as a scientific advisor for a range of biotechnology companies both in the US and the Netherlands. He is an author on more than 50 peer-reviewed papers and an inventor on more than 30 US patents.

Dr. Heyneker replaces Jaap Goudsmit, M.D., Ph.D. who has retired from the Board of Directors of Vaxin, as Crucell's Board representative. "We greatly appreciate Jaap's dedicated service and contribution to building and growing the company over the past several years," Dr. Hohnke added.

About Vaxin:

Vaxin Inc. is an emerging clinical stage vaccine company developing needle-free, single dose highly safe and effective vaccines. These molecular vaccines are safely administered either in the nose or on the skin, taking the battle against diseases to the immune system's front lines where the diseases are attacking, rather than injecting the vaccine inside the body where the body's immune response is

actually weaker. This delivery mechanism also allows Vaxin's vaccines to be mass administered by personnel without sophisticated medical training.

As a vaccine delayed may be a vaccine denied, it is crucial to produce vaccines in a timely manner, especially in the event of a pandemic or bioterrorist attack. The company's technology platform provides a critical tool for the rapid production of vaccines against influenza, avian influenza and anthrax utilizing molecular techniques and state of the art cell culture based manufacturing. Vaxin's vaccines are not dependent on chicken eggs and can therefore be more reliably produced even in the event of avian epidemics.

Vaxin's unique technology was developed by Dr. De-chu C. Tang, Vaxin's scientific founder and Vice President of Research. Unlike current vaccines, which typically use a weakened form of the targeted disease, such as the influenza virus, Vaxin's molecular vaccines are created by inserting only a piece of the influenza virus (the gene encoding an antigen) into a benign delivery vehicle. This "Trojan Horse" method increases the safety of the vaccine and virtually eliminates the risk of a vaccine reverting to a disease causing agent. Needle-free, non-replicating, single-dose molecular vaccines also have many other advantages. Patients clearly prefer vaccines which are not injected because there is no fear of needles or the pain they can cause.

Vaxin's technology also has applications for animal health. Automated *in ovo* (in the egg) vaccination is the method of choice for the mass immunization of poultry because of the ease of administration and lower costs. Unlike most technologies that have been tried, Vaxin's technology safely introduces a protective vaccine into the egg without harming the embryo.

Forward-looking statements:

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

#